Partner Brent Babcock Comments on CRISPR Patent Decision
Partner Brent Babcock, Chair of the firm's USPTO Trials & Post-Grant Proceedings group, was quoted in "Editas breathes sigh of relief as CRISPR ruling handed down," an article published in MedCity News.